Emdeon opens for trading today on NYSE

Emdeon Inc. opened for trading today on the New York Stock Exchange under the ticker symbol “EM” after its successful initial public offering in which it raised $367 million in gross proceeds. Headquartered in Nashville, Tenn., Emdeon is the 13th IPO by an operating company, including non-U.S. companies, and the 10th U.S. domestic IPO to list on the New York Stock Exchange this year.

“We congratulate Emdeon on the successful completion of its IPO,” said Scott R. Cutler, NYSE Euronext EVP and Head of Listings, Americas. “Emdeon is an innovative, technology-oriented healthcare services company and a welcome addition to the NYSE. We look forward to a lasting partnership with the company and its stockholders.”

To celebrate the company’s IPO and NYSE listing, Emdeon, led by George I. Lazenby, Chief Executive Officer, will ring the NYSE Opening Bell on August 25th.

Emdeon is the 10th U.S. initial public offering to begin trading on the New York Stock Exchange this year among a roster of leading companies that have chosen to go public on the NYSE: Mead Johnson Nutrition Company (NYSE: MJN), which raised $828 million in proceeds; Rosetta Stone (NYSE: RST), which raised $129 million in proceeds; Bridgepoint Education (NYSE: BPI), which raised $163 million in proceeds; DigitalGlobe (NYSE: DGI), which raised $279.3 million in proceeds, and SolarWinds, Inc. (NYSE: SWI) which raised $151.5million.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.